{"id":354413,"date":"2026-01-19T23:04:18","date_gmt":"2026-01-19T17:34:18","guid":{"rendered":"https:\/\/forumias.com\/blog\/?page_id=354413"},"modified":"2026-01-19T23:04:18","modified_gmt":"2026-01-19T17:34:18","slug":"answered-analyze-the-resilience-of-bharats-anti-evergreening-patent-regime-against-intensifying-global-trade-pressures-evaluate-whether-the-strategic-utilization-of-legal","status":"publish","type":"page","link":"https:\/\/forumias.com\/blog\/answered-analyze-the-resilience-of-bharats-anti-evergreening-patent-regime-against-intensifying-global-trade-pressures-evaluate-whether-the-strategic-utilization-of-legal\/","title":{"rendered":"[Answered] Analyze the resilience of Bharat\u2019s \u2018anti-evergreening\u2019 patent regime against intensifying global trade pressures. Evaluate whether the strategic utilization of legal levers, such as Compulsory Licensing, is essential to reconcile intellectual property obligations with the constitutional mandate of ensuring affordable healthcare."},"content":{"rendered":"

Introduction<\/strong><\/h2>\n

Bharat\u2019s patent regime, shaped by TRIPS flexibilities, Section 3(d)<\/strong> and constitutional commitments under Article 21<\/strong>, faces renewed global trade pressures, raising critical questions on balancing innovation, sovereignty and affordable public health.<\/p>\n

Resilience of Bharat\u2019s Anti-Evergreening Patent Regime<\/strong><\/h2>\n
    \n
  1. Bharat\u2019s patent framework is internationally recognised for its resistance to \u2018evergreening\u2019\u2014the practice of extending monopolies <\/strong>through incremental, non-therapeutic modifications.<\/li>\n
  2. Section 3(d) of the Patents Act, 1970<\/strong> acts as a statutory sentinel by requiring \u2018significant enhancement of therapeutic efficacy\u2019 for patentability of derivatives. This design reflects a conscious policy choice to prioritise access over monopoly rents.<\/li>\n
  3. The robustness of this regime was judicially affirmed in Novartis AG v. Union of India (2013), where the Supreme Court rejected<\/strong> patent protection for Imatinib Mesylate (Gleevec), clarifying that improved bioavailability<\/strong> or storage stability does not equate to enhanced therapeutic efficacy. This decision preserved India\u2019s generic pharmaceutical ecosystem, enabling affordable cancer treatment domestically and across the Global South.<\/li>\n
  4. Empirically, this resilience has translated into outcomes: according to WHO estimates, Indian generics reduce drug prices by 60\u201390% globally<\/strong>, while Bharat supplies nearly 20% of global generic medicines<\/strong> by volume. However, this public-health-oriented stance increasingly attracts geopolitical friction.<\/li>\n
  5. Trade instruments such as the US \u2018Special 301\u2019 Watch List and tariff threats<\/strong> against Indian pharmaceutical exports exemplify \u2018hubris-driven tariff sabre-rattling\u2019<\/strong> aimed at softening India\u2019s IPR posture.<\/li>\n<\/ol>\n

    Global Trade Pressures and the TRIPS Context<\/strong><\/h2>\n
      \n
    1. Under the WTO\u2019s TRIPS Agreement, Bharat is<\/strong> obliged to protect intellectual property but retains sovereign policy space through explicit flexibilities.<\/li>\n
    2. The Doha Declaration on TRIPS and Public Health (2001)<\/strong> unequivocally affirms that member states may prioritise public health and promote access to medicines for all.<\/li>\n
    3. Despite this legal cover, Bharat has exercised restraint. Since 2005, only<\/strong> one compulsory licence\u2014Natco v. Bayer (2012) for Nexavar<\/strong>\u2014has been issued, reducing prices by nearly 97%. This underutilisation reflects concerns over investor sentiment, retaliatory tariffs and R&D flight, rather than legal incapacity.<\/li>\n<\/ol>\n

      Strategic Utilisation of Legal Levers: Necessity, Not Extremism<\/strong><\/h2>\n
        \n
      1. A calibrated activation of statutory levers is essential to reconcile IPR obligations with constitutional mandates. Article 21, as interpreted in Paschim Banga Khet Mazdoor Samity and Mohinder Singh Chawla<\/strong>, imposes a positive obligation on the state to ensure access to healthcare.<\/li>\n
      2. Beyond compulsory licensing under Sections 84 and 92, Bharat\u2019s Patents Act<\/strong> provides underexplored tools:<\/li>\n<\/ol>\n